Abstract: Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes. It is the main cause of acquired vision loss in adults all over the world. Because the initial symptoms are not obvious and patients do not have enough recognition of the disease, it leads to the deterioration of the disease and blindness. Therefore, the research and development of hypoglycemic drugs to delay diabetic retinal complications get attention from the majority of scholars. Numerous studies have found that sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) can lower blood glucose and delay the progress of diabetic retinal complications. This article reviews the early pathological changes of DR and the clinical and experimental evidences of the protective effect of SGLT-2i on DR.

Key words: Diabetic retinopathy, Sodium-glucose cotransporter 2 inhibitor, Dapagliflozin

摘要： 糖尿病视网膜病变（diabetic retinopathy，DR）是糖尿病最常见的微血管并发症之一。因为该病初期症状不明显，患者对疾病认知不够，导致病情恶化，严重可导致失明。它是全球成年人获得性视力丧失的主要原因。因此延缓糖尿病视网膜并发症降糖药物的研发受到广大学者的关注。研究发现钠-葡萄糖协同转运蛋白2（sodium-glucose cotransporter 2，SGLT2）抑制剂（SGLT2 inhibitor，SGLT2i）在降低血糖的同时能延缓糖尿病视网膜并发症的进展。本文将主要对DR早期改变及SGLT-2i对DR保护作用的临床和实验证据进行综述。

关键词: 糖尿病视网膜病变, 钠-葡萄糖协同转运蛋白2抑制剂, 达格列净